Baldwin Brothers Inc. MA lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,780 shares of the company’s stock after selling 727 shares during the quarter. Baldwin Brothers Inc. MA’s holdings in Johnson & Johnson were worth $4,584,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $105,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $117,000. Princeton Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $141,000. Smart Portfolios LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $150,000. Finally, Live Your Vision LLC lifted its stake in shares of Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after buying an additional 502 shares during the last quarter. Hedge funds and other institutional investors own 66.67% of the company’s stock.
NYSE:JNJ opened at $139.46 on Thursday. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The stock has a market cap of $370.70 billion, a P/E ratio of 19.12, a price-to-earnings-growth ratio of 2.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same period last year, the firm earned $1.90 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 8.14 earnings per share for the current year.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by company insiders.
A number of analysts have recently issued reports on JNJ shares. Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, July 13th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Finally, ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $144.25.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Why do earnings reports matter?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.